ZYBERNO
Stock Report
Updated Sep 1, 2026

DRUGS MADE IN AMERICA ACQUISITION II CORP. (DMII)

Financial Services • NASDAQ

$10.14

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
DRUGS MADE IN AMERICA ACQUISITION II CORP. (DMII) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-0.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

DRUGS MADE IN AMERICA ACQUISITION II CORP. (DMII) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:10.14
Market Cap:$645.28M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$645.56M

Price Action & Momentum (1)

% of 52-Week High:99.3%
B. Profitability Assessment

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.34x
Quick Ratio:0.34x
Cash Ratio:0.27x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-426,751.00
Cash And Cash Equivalents:174,974.00
Long Term Debt:$0.00
Net Debt:$275.03K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$488.39K

Bottom Line Performance (3)

$4.19M
Income Before Tax:$0.00
Ebitda Ttm:-488,385.00

Operating Expenses (5)

Operating Expenses:112,227.00
R And D Expense:0.00
Sga Expense:112,227.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$514.10M
Current Assets:$217.82K
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:532,026,907.00
Current Liabilities:644,574.00
Long Term Debt:$0.00
Short Term Debt:$450.00K

Equity & Capital (3)

Equity:-$17.93M
Retained Earnings:-$17.93M
Common Stock:220,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:69,159.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$1.02M$0.00

Investment Activities (1)

Investing Cash Flow:-$500.00M

Financing Activities (3)

Financing Cash Flow:$450.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:500,000,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:$0.07

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.02

Book Value & Capital (2)

Book Value Per Share:-$0.28
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:DMII
Company Name:DRUGS MADE IN AMERICA ACQUISITION II CORP.
Sector:Financial Services
Industry:Blank Checks
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:63.64M
Shares Outstanding Basic:13.70M
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 16:40:16 UTC
Data Timestamp:2026-09-01T16:40:16.730907
Scroll to Top